Table 1.
Total number of patients | 88 |
---|---|
Patients' sex (male/female) | 62/26 |
Median (range) | |
Age (years) | 70 (50–90) |
OS (months) | 42 (4–120) |
White blood cells (×106/mL) | 32,250 (8500–96,900) |
Lymphocytes (×106/mL) | 23,050 (5300–69,430) |
CD38 expression (mean optical intensity of staining) | 7.7 (0.10–59.2) |
Early apoptosis index (55/88 patients) | 4.7 (0.01–54.8) |
Number of patients (%) | |
Binet stage | |
A | 50 (56.8%) |
B | 16 (18.2%) |
C | 22 (25.0%) |
Rai stage | |
0 | 16 (18.2%) |
I | 27 (30.7%) |
II | 24 (27.3%) |
III | 4 (4.5%) |
IV | 17 (19.3%) |
Risk group | |
Low | 16 (18.2%) |
Intermediate | 51 (58.0%) |
High | 21 (23.9%) |
Serum LDH concentration | |
Normal | 60 (68.2%) |
Elevated | 28 (31.8%) |
CD38 expression status | |
Negative | 73 (83.0%) |
Positive | 15 (17.0%) |
IGHV mutational status | |
Mutated | 45 (51.1%) |
Unmutated | 43 (48.9%) |
CLL: chronic lymphocytic leukemia; OS: overall survival; LDH: lactate dehydrogenase; IGHV: immunoglobulin heavy chain variable region.